Back

A heterogeneous pool of tumor precursor cells with self-replenishing and tumor-originating properties in Chronic Lymphocytic Leukemia

Budeus, B.; Dampmann, M.; Kibler, A.; Fassbender, B.; Brauser, M.; Bronischewski, K.; Homp, E.; Taudien, S.; Johansson, P.; Bloehdorn, J.; Stilgenbauer, S.; von Tresckow, J.; Duerig, J.; Reinhardt, H. C.; Kueppers, R.; Dietrich, S.; Seifert, M.

2024-07-18 cancer biology
10.1101/2022.05.04.490383 bioRxiv
Show abstract

Intratumor heterogeneity (ITH) refers to the coexistence of distinct cancer cell subpopulations within a single tumor, each with unique molecular and functional properties. Understanding the dynamics and evolution of ITH is crucial for predicting tumor progression and the development of therapy resistance. Here, we conducted a comprehensive investigation of ITH in Chronic Lymphocytic Leukemia (CLL) and identified a subpopulation that carried the CLL B-cell receptor rearrangement but contrasted from the CLL main population by low CD5 and high CD20 expression and highly mutated Ig-genes. This CLL-related memory B-cell population shared somatic driver mutations with the main CLL population but also exhibited exclusive somatic mutations. Phylogenetic analysis suggested a pathogenically early generation of these CLL-related B cells before monoclonal B lymphocytosis or CLL manifestation. Our data indicated that CLL-related B cells have self-replenishing potential, as they diminish upon treatment but recover indistinguishably on relapse. This contrasts with the main CLL population, which mostly represents a selective and novel expansion of the CLL-related B cells. This differentiation capacity into conventional CLL cells, and the expression of leukemic stem cell signatures further supported their tumorigenic capacity. We propose that these CLL-related B cells represent a pool of highly diversified, early-stage CLL precursor cells, which persist in the shape of "malignant memory B cells". Longitudinal analyses of these CLL precursor cells suggested that they form a reservoir of malignant, leukemia-originating cells which contribute during disease progression to CLL outgrowth and clonal evolution.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
HemaSphere
16 papers in training set
Top 0.1%
26.2%
2
Blood
74 papers in training set
Top 0.2%
9.5%
3
Leukemia
42 papers in training set
Top 0.2%
6.2%
4
Blood Advances
62 papers in training set
Top 0.3%
5.5%
5
eLife
5828 papers in training set
Top 22%
5.4%
50% of probability mass above
6
Frontiers in Immunology
638 papers in training set
Top 3%
4.0%
7
Journal of Experimental Medicine
119 papers in training set
Top 0.8%
3.2%
8
Blood Cancer Journal
14 papers in training set
Top 0.1%
3.1%
9
Cell Reports
1498 papers in training set
Top 14%
2.6%
10
Cell Reports Medicine
153 papers in training set
Top 1%
2.4%
11
Genome Research
468 papers in training set
Top 3%
2.1%
12
Nature Communications
5641 papers in training set
Top 45%
1.7%
13
Genome Medicine
183 papers in training set
Top 3%
1.7%
14
European Journal of Immunology
60 papers in training set
Top 0.9%
1.5%
15
Communications Biology
993 papers in training set
Top 17%
1.5%
16
Life Science Alliance
285 papers in training set
Top 4%
1.4%
17
Cancers
213 papers in training set
Top 4%
1.1%
18
Haematologica
25 papers in training set
Top 0.5%
1.1%
19
Molecular Oncology
55 papers in training set
Top 1%
1.1%
20
eBioMedicine
183 papers in training set
Top 4%
1.1%
21
Scientific Reports
3612 papers in training set
Top 66%
1.1%
22
EMBO Molecular Medicine
95 papers in training set
Top 3%
0.8%
23
OncoImmunology
24 papers in training set
Top 0.7%
0.8%
24
iScience
1154 papers in training set
Top 36%
0.8%
25
Cells
249 papers in training set
Top 7%
0.8%
26
Cancer Research Communications
51 papers in training set
Top 2%
0.8%
27
Computational and Structural Biotechnology Journal
242 papers in training set
Top 8%
0.6%